R&D channel feed – Endpoints News

R&D channel feed

As market stays cold, biotechs continue to cut programs, trials and staff

3 years ago

OncoSec reports flop for IL-12/Keytruda combo in what may be final blow

3 years ago

Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug

3 years ago

Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial

3 years ago

AstraZeneca inks deal with Japanese biotech JCR in CNS indication

3 years ago

FTC orders Illumina to divest Grail, adding pressure amid activist fight with Icahn

3 years ago

Takeda pays $5M upfront to license antibodies for celiac disease drug development

3 years ago

Cytokinetics’ ALS drug fails PhIII, leaving the biotech with a single late-stage prospect

3 years ago

CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations

3 years ago

Austin biotech Molecular Templates lays off more than 100 staffers as pipeline narrows

3 years ago

Aptinyx evaluates future of the company following two failed trials, 60% layoffs

3 years ago

Nanoscope’s eye disease gene therapy shows mixed results in PhII

3 years ago

Daiichi Sankyo inks $183M discovery deal with GPCR biotech for CNS target

3 years ago

Diffusion to hand Nasdaq spot to EIP Pharma for PhIIb dementia study of ex-Vertex drug

3 years ago

Seelos Therapeutics 'temporarily' stops study in rare neuro disorder for business reasons

3 years ago

Alector cuts 11% of workforce as it doubles down on late-stage neuro programs partnered with GSK, AbbVie

3 years ago

In search of new way to deliver gene editors, CRISPR pioneer turns to molecular syringes

3 years ago

J&J bows out of RSV vaccine race, ending PhIII study and ceding to Pfizer, GSK

3 years ago

No longer ‘dead or just hibernating,’ drugmakers return to heart medicines

3 years ago

Vanda wins court case against FDA over disclosure of CRL details for sleep drug

3 years ago

Tiny multiomics biotech secures former J&J drug, new execs and new financing

3 years ago

Intra-Cellular Therapies gets a boost on PhIII depression drug data

3 years ago

Viking soars on early-stage weight loss data as it maps out PhII

3 years ago

Gunning for 2023 approval, GSK details PhIII data for Jemperli in frontline endometrial cancer

3 years ago

First page Previous page 90 91 929394 95 96 Next page Last page